Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

In recent years, CD133 has been identified as a cancer stem cell (CSC) marker in gliomas. Nevertheless, the clinical and prognostic value of CD133 in glioma patients remains controversial. Therefore, we conducted a systematic meta-analysis to evaluate the correlation of CD133 with World Health Organization (WHO) grade, age, gender, overall survival (OS), and progression-free survival (PFS) in glioma patients. Eligible studies on this subject were included, and then pooled odd ratios (ORs) and hazard ratios (HRs) with 95 % confidence intervals (95 % CIs) were estimated. Publication bias was assessed by the funnel plots, and heterogeneity and sensitivity were analyzed as well. In the present study, 21 articles with the total number of 1535 patients were included. High expression of CD133 in glioma patients was associated with high WHO grade (III + IV) (n = 11, OR 5.10, 95 % CI 2.99–8.69; p = 0.000), rather than age (n = 4, OR 2.54, 95 % CI 0.68–9.52; p = 0.167) and gender (n = 4, OR 0.71, 95 % CI 0.21–2.45; p = 0.587). In addition, survival analysis demonstrated a significant association between CD133 high expression and poor 2-year OS (n = 11, HR 2.18, 95 % CI 1.29–3.7; p = 0.004), 5-year OS (n = 4, HR 10.39, 95 % CI 2.59–41.63; p = 0.001), as well as PFS (n = 10, HR 2.34, 95 % CI 1.62–3.37; p = 0.000). Taken together, this study suggests that CD133 expression correlates to higher grade of gliomas and worse prognosis in glioma patients. Thus, CD133 could be recommended as a useful pathological and prognostic biomarker in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cheng Y, Zhao J, Qiao W, Chen K (2014) Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. Am J Nucl Med Mol Imaging 4(5):385–405

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507

    Article  CAS  PubMed  Google Scholar 

  3. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells: perspectives on current status and future directions—AACR workshop on cancer stem cells. Cancer Res 66(19):9339–9344

    Article  CAS  PubMed  Google Scholar 

  4. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, Cao B, Liu C, Wu G, Ao H, Zhang X, Jiang J (2013) Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci 110(17):6829–6834

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68(23):9703–9711

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110

    Article  PubMed  Google Scholar 

  7. Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99(8):1285–1289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62(8):1212–1218

    Article  CAS  PubMed  Google Scholar 

  9. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, Ikemoto T (2010) CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45(8):896–902

    Article  CAS  PubMed  Google Scholar 

  10. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14(1):123–129

    Article  CAS  PubMed  Google Scholar 

  11. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J (2008) Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 27:85

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Dahlrot RH, Hansen S, Jensen SS, Schrøder HD, Hjelmborg J, Kristensen BW (2014) Clinical value of CD133 and nestin in patients with glioma: a population-based study. Int J Clin Exp Pathol 7(7):3739–3751

    PubMed  PubMed Central  Google Scholar 

  13. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18(4):705–719

    Article  CAS  PubMed  Google Scholar 

  14. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1):16

    Article  PubMed  PubMed Central  Google Scholar 

  15. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834

    Article  CAS  PubMed  Google Scholar 

  16. Sterne JA, Egger M (2001) Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. J Clin Epidemiol 54(10):1046–1055

    Article  CAS  PubMed  Google Scholar 

  17. Li SZ, Huang W, Yang LT, Yu YJ, Huang GX, Huang CJ (2014) Expression of CD133, SSEA 1 and Nestin in human gliomas and its significance. Chin J Minim Invasive Neurosurg 19(7):327–330

    Google Scholar 

  18. Shin JH, Lee YS, Hong YK, Kang CS (2013) Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. J Neurooncol 115(3):333–341

    Article  CAS  PubMed  Google Scholar 

  19. Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C, Tominaga T (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol 15(9):1151–1159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Xing PH, Lv ZQ, Zhang XX, Liu HY, Tong J, Liu YZ, Zhang L, Yuan JW (2013) Study on correlations among the expression of HIF-1, MGMT and CD133 in human glioblastoma. Chin J Nerv Ment Dis 39(9):523–527

    CAS  Google Scholar 

  21. Pan L, Kong LJ, Sun JN, Liang CH (2013) Relationship between expression of CD133 in glioma tissue and vascular formation. Harbin Med J 33(5):337–338

    Google Scholar 

  22. Zhu ZW (2013) The expression and clinical significance of CD133 and CDl66 in gliomas. South Med Univ 1(1):18–21

    Google Scholar 

  23. Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A (2012) MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med 10:250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kong LJ, Jiao BH, Zhang AJ, Cui GS, Sun JN, Li FM, Li SB (2012) Expressions and distribution characteristics of CD133 and nestin positive cells in glioma. Mod Oncol 20(9):1820–1824

    CAS  Google Scholar 

  25. Ma Q (2012) Expression and clinical significance of MMP-9 and CDl33 protein in human gliomas. Jinan Univ 1(1):8–12

    Google Scholar 

  26. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R, Larocca LM (2011) Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer 117(1):162–174

    Article  PubMed  Google Scholar 

  27. Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D (2011) Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol 18(10):2937–2945

    Article  PubMed  Google Scholar 

  28. Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S, Lee MC (2011) The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 31(5):494–502

    Article  PubMed  Google Scholar 

  29. He J, Shan Z, Li L, Liu F, Liu Z, Song M, Zhu H (2011) Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. Oncol Rep 26(5):1305–1313

    CAS  PubMed  Google Scholar 

  30. Ke J, Hu XM, Zhou SY, He J, Zhu HQ (2011) Distribution of tumor stem cell and the relationship with p53 and MGMT in glioma. J Mod Oncol 19(7):1322–1324

    CAS  Google Scholar 

  31. Guo CY, Jiao BH, Liang ZH, Lu SK (2011) The significance of immunohistochemical double staining of CD133/PCNA and Nestin/PCNA coexpression in the basic and clinical glioma research. J Hebei Med Univ 32(7):774–777

    CAS  Google Scholar 

  32. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB (2010) Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol 96(3):359–367

    Article  CAS  PubMed  Google Scholar 

  33. Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X (2008) Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS One 3(4):e1936

    Article  PubMed  PubMed Central  Google Scholar 

  34. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R (2008) Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14(24):8205–8212

    Article  CAS  PubMed  Google Scholar 

  35. Irollo E, Pirozzi G (2013) CD133: to be or not to be, is this the real question? Am J Transl Res 5(6):563–581

    PubMed  PubMed Central  Google Scholar 

  36. Begg CB, Berlin JA (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc A 81(2):107–115

    Google Scholar 

Download references

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81172404, 81372720), Special Foundation for Taishan Scholars (TS20110814). We were also very grateful to the help of Yunyun Guo et al. for their valuable advice.

Conflict of Interest

The authors state that there are no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, 107 Wen Hua Xi Road, Jinan, Shandong, 250012, China

    Mingzhi Han, Bin Huang, Anjing Chen, Weiliang Chen & Xingang Li

  2. Jining No.1 People’s Hospital, Jining, Shandong, China

    Laixiu Guo

  3. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China

    Ya Zhang

  4. School of Medicine, Shandong University, Jinan, Shandong, China

    Mingzhi Han, Ya Zhang, Xupeng Liu, Shicheng Sun, Kun Wang & Ao Liu

Authors
  1. Mingzhi Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laixiu Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ya Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anjing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weiliang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xupeng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shicheng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xingang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xingang Li.

Additional information

Mingzhi Han and Laixiu Guo contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Han, M., Guo, L., Zhang, Y. et al. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis. Mol Neurobiol 53, 720–727 (2016). https://doi.org/10.1007/s12035-014-9018-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-014-9018-9

Keywords

Search

Navigation